Synergy Pharmaceuticals
SGYP
SGYP was delisted on the 7th of March, 2019.
80 hedge funds and large institutions have $142M invested in Synergy Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 35 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
119% more call options, than puts
Call options by funds: $1.55M | Put options by funds: $709K
103% more capital inflows, than outflows
Capital inflows: $21.6M | Capital outflows: $10.6M
11% more funds holding
Funds holding: 72 → 80 (+8)
2.46% more ownership
Funds ownership: 26.42% → 28.88% (+2.5%)
11% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$11.4M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.12M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.56M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$861K |
| 5 |
ProShare Advisors
Bethesda,
Maryland
|
+$585K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$4.97M |
| 2 |
Bailard
Foster City,
California
|
-$1.29M |
| 3 |
Wolverine Asset Management
Chicago,
Illinois
|
-$850K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$634K |
| 5 |
Oxford Asset Management
Oxford,
United Kingdom
|
-$414K |
SGYP Hedge Fund Activity: Q1 2014 in Review
80 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals (SGYP) for Q1 2014, worth a combined $142M — up 2.2% from $139M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new SGYP positions and 6 closed out — a net gain of 8 holders — while 31 added to existing stakes and 35 trimmed.
The largest buyer was State Street, adding an estimated $11.4M. The largest seller was Baker Bros. Advisors, cutting an estimated $4.97M.
- 80 institutional investors held Synergy Pharmaceuticals (SGYP) as of Q1 2014, up from 72 in Q4 2013.
- Funds reported $142M of Synergy Pharmaceuticals stock for Q1 2014, up 2.2% quarter-over-quarter.
- 14 funds opened new Synergy Pharmaceuticals positions in Q1 2014 and 6 closed out, a net change of +8 holders.
- The largest Synergy Pharmaceuticals buyer in Q1 2014 was State Street, an estimated $11.4M added.
- The largest Synergy Pharmaceuticals seller in Q1 2014 was Baker Bros. Advisors, an estimated $4.97M sold.
Based on aggregated 13F filings for Q1 2014.